RC Medical is flipping the traditional medical device development model on its head. Rather than starting with an engineer's concept and searching for a clinical application, the Lake Forest, California-based venture studio begins in the interventional suite, listening to physicians describe the gaps they encounter weekly. That approach, according to CEO David Ferrera, is central to the studio's mission to fund, design, develop, and commercialize products for the interventional radiology market.
The significance of this model lies in its potential to address a long-standing challenge in medical technology: many physician-identified problems never make it onto a traditional product roadmap. Ferrera, who has spent nearly three decades building devices for interventional neuroradiology, including as co-founder of Blockade Medical and chief technology officer of Balt Global, argues that details visible only to practicing physicians are often missed when devices are built for them rather than with them. "A catheter that works in a textbook case can still fail in the specific anatomy a physician sees three times a week," he said. "That detail doesn't show up unless you're building with the physician, not for them."
RC Medical's structure is designed to capture those details early. When a physician brings an idea to the studio, it is treated as a partnership that runs from first sketch through commercialization. The physician remains close to the clinical need while RC Medical manages engineering, regulatory pathways, funding, and business formation. If an idea clears an initial evaluation, the studio does not fold it into an existing product line. Instead, it forms a new company around it. "Each idea gets its own company, its own team, its own focus," Ferrera said. "A big portfolio company can lose a good idea in the shuffle. A newco can't afford to."
That strategy has already yielded three standalone companies: Single Pass, Infinity Neuro, and Sonorous NV. Each originated from a specific problem described by a physician in the interventional suite and now operates as an independent business. The creation of these companies suggests the model can generate tangible outcomes, not just concepts.
Ferrera is candid that the studio is not suited to every idea. "Some ideas are better as a feature of an existing product, not a new company," he said. "Part of the first conversation is being honest about which one this is." For ideas that do become newcos, physician involvement typically continues through development and toward market, keeping the clinical need in view at every stage. That sustained collaboration could be a key differentiator in a field where device failure often stems from design assumptions that do not hold in real-world anatomy.
The venture studio model also has implications for how medical device innovation is funded and commercialized. By forming dedicated companies, RC Medical can attract focused investment and talent for each project, potentially speeding development timelines and improving success rates. For physicians with promising ideas, the studio offers a path to translate clinical insight into a product without bearing the full burden of engineering and regulatory work alone. Ferrera, author of "Innovation in Translation: How Big Ideas Really Happen," published by Forbes Books in 2021, positions the studio as a bridge between clinical practice and industry, one that could reshape how interventional radiology devices reach patients.
